November 2020

Contents

Editorial

HTB: no. 12 – HIV and COVID-19: issue 9 (11 November 2020)

Special reports

Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine

Conference reports

HIV Therapy Glasgow 2020

Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19

51st World Conference on Lung Health

No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts

International workshop on clinical pharmacology of HIV, hepatitis, and other antiviral drugs

New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet

Antiretrovirals

EMA issues positive opinion to approve cabotegravir LA/rilpivirine LA injections (Vocabria/Rekambys) as new HIV treatment

HIV prevention and transmission

HIV in the UK: diagnoses continued to fall during 2019 but 42% are still late

Two-monthly cabotegravir injections prevent HIV infection in African women: HPTN 084 study recommends early unblinding

On the web

AIDS 2020: Virtual online translated resources

COVID-19: HIV and COVID-19 coinfection

COVID-19 antibody testing for HIV positive people in the UK: HIV organisations reverse previous exclusion

HIV positive people at higher risk of worse outcomes from COVID-19 in UK study

COVID-19: investigational drugs

Remdesivir given full approval by the US FDA, but on limited data

DSMB stops REGN-COV2 (casirivimab/imdevimab) monoclonal antibody study in people with high-flow oxygen or ventilation: implications for UK RECOVERY study

Monoclonal antibody stopped in ACTIV-3 study: bamlanivimab shows lack of benefit in people hospitalised with COVID-19

Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19

No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study

PDFs

HTB no 12 – plus: HIV and COVID-19 bulletin no 9 (11 November 2020)